Due to the presence of, inter alia, high levels of PD-1+ CD8+ T cells in the tumour microenvironment, especially at relapse after bone marrow transplant, AML is a potential candidate for therapeutic modulation of that immune checkpoint molecule [8,9]. This evidence concerns the gene CD8A and acute myeloid leukemia.